Expression of aberrantly glycosylated Mucin-1 in ovarian cancer

Histopathology

Volumn 57, Issue 4, 2010, Pages 597-606

  Van Elssen, Catharina H M J ^a,b   Frings, Peter W H ^a   Bot, Freek J ^a   Van De Vijver, Koen K ^a   Huls, Mariska B ^a   Meek, Bob ^a   Hupperets, Pierre ^a   Germeraad, Wilfred T V ^a   Bos, Gerard M J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PharmaCell BV   (Netherlands)

Author keywords

Mucin 1 and glycosylation; Ovarian adenocarcinoma; STn; Tn; Tumour associated antigen

Indexed keywords

EPITOPE; MUCIN 1; PARAFFIN; TUMOR ANTIGEN;

ARTICLE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; EPITOPE MAPPING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MUCINOUS CARCINOMA; OVARY ADENOCARCINOMA; OVARY CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION;

ADENOCARCINOMA; EPITOPES; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; MUCIN-1; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650450703     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03667.x     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 2009; 59; 225-249.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55; 74-108.
3. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. 2004; 351; 2519-2529.
4. Salzberg M, Thurlimann B, Bonnefois H et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005; 68; 293-298.
5. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 2005; 24; 487-499.
6. Frederick PJ, Straughn JM Jr, Alvarez RD, Buchsbaum DJ. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol. Oncol. 2009; 113; 384-390.
7. Singh AP, Senapati S, Ponnusamy MP et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 2008; 9; 1076-1085.
8. Gendler SJ. MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia 2001; 6; 339-353.
9. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim. Biophys. Acta 1999; 1455; 301-313.
10. Ho SB, Niehans GA, Lyftogt C et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993; 53; 641-651.
11. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod. Biol. Endocrinol. 2004; 2; 4.
12. Cloosen S, Gratama J, Van Leeuwen EB et al. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br. J. Haematol. 2006; 135; 513-516.
13. Ichige K, Perey L, Vogel CA, Buchegger F, Kufe D. Expression of the DF3-P epitope in human ovarian carcinomas. Clin. Cancer Res. 1995; 1; 565-571.
14. Burchell JM, Mungul A, Taylor-Papadimitriou J. O-linked glycosylation in the mammary gland: changes that occur during malignancy. J. Mammary Gland Biol. Neoplasia 2001; 6; 355-364.
15. Von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur. J. Cancer 1996; 32A; 1325-1331.
16. Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol. Immunother. 1998; 46; 245-252.
17. Springer GF. T and Tn, general carcinoma autoantigens. Science 1984; 224; 1198-1206.
18. Van Leeuwen EB, Cloosen S, Senden-Gijsbers BL et al. Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector. Cytotherapy 2006; 8; 24-35.
19. Marcos NT, Pinho S, Grandela C et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 2004; 64; 7050-7057.
20. Ju T, Lanneau GS, Gautam T et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008; 68; 1636-1646.
21. Sørensen AL, Reis CA, Tarp MA et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006; 16; 96-107.
22. Tarp MA, Sørensen AL, Mandel U et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007; 17; 197-209.
23. Karsten U, Von Mensdorff-Pouilly S, Goletz S. What makes MUC1 a tumor antigen? Tumour Biol. 2005; 26; 217-220.
24. Giuntoli RL II, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA. Mucin gene expression in ovarian cancers. Cancer Res. 1998; 58; 5546-5550.
25. Feng H, Ghazizadeh M, Konishi H, Araki T. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn. J. Clin. Oncol. 2002; 32; 525-529.
26. Tashiro Y, Yonezawa S, Kim YS, Sato E. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum. Pathol. 1994; 25; 364-372.
27. Mandai M, Yamaguchi K, Matsumura N, Baba T, Konishi I. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int. J. Clin. Oncol. 2009; 14; 383-391.
28. Scully RE. Classification of human ovarian tumors. Environ. Health Perspect. 1987; 73; 15-25.
29. Wesseling J, Van Der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 1995; 129; 255-265.
30. Burchell J, Gendler S, Taylor-Papadimitriou J et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987; 47; 5476-5482.
31. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer 1989; 43; 1072-1076.
32. Cloosen S, Arnold J, Thio M, Bos GM, Kyewski B, Germeraad WT. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res. 2007; 67; 3919-3926.
33. Jimbo H, Hitomi Y, Yoshikawa H et al. Evidence for monoclonal expansion of epithelial cells in ovarian endometrial cysts. Am. J. Pathol. 1997; 150; 1173-1178.
34. Nilbert M, Pejovic T, Mandahl N, Iosif S, Willen H, Mitelman F. Monoclonal origin of endometriotic cysts. Int. J. Gynecol. Cancer 1995; 5; 61-63.
35. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum. Pathol. 2009; 40; 1213-1223.
36. Croce MV, Isla-Larrain MT, Capafons A, Price MR, Segal-Eiras A. Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res. Treat. 2001; 69; 1-11.
37. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 1994; 54; 2856-2860.
38. Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, Von Mensdorff-Pouilly S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett. 2007; 257; 47-55.
39. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2007; 16; 30-35.
40. Nassar H, Pansare V, Zhang H et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod. Pathol. 2004; 17; 1045-1050.
41. Van De Wiel-van Kemenade E, Ligtenberg MJ, De Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 1993; 151; 767-776.
42. Akporiaye ET, Bradley-Dunlop D, Gendler SJ et al. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine 2007; 25; 6965-6974.
43. Apostolopoulos V, Pietersz GA, Tsibanis A et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006; 8; R27.
44. Loveland BE, Zhao A, White S et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 2006; 12; 869-877.